Bastide le Confort Medical AI Stock Analysis
Want to see FR:BLC full AI Analyst Report?
Bastide le Confort Medical (BLC) AI Stock Analysis
Bastide le Confort Medical
(Paris:BLC)
Bastide le Confort Medical scores modestly above average. The strongest support comes from financial discipline: consistent operating cash flow, expanding EBIT and EBITDA margins, and a major deleveraging that cut debt-to-equity from 5.7x to 2.3x. However, revenue has declined for two consecutive years and the eye-catching €58.1M profit appears largely non-recurring, leaving underlying earnings quality weak. The share price trend is the main drag, trading below all key moving averages with negative MACD momentum. A very low P/E offers potential value, but the absence of a dividend and the questionable earnings base temper that appeal.
Bastide le Confort Medical (BLC) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 143.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,549
- Price to Earnings (P/E)
- 2.5
- Beta (1Y)
- 0.57
- Revenue Growth
- -1.79%
- EPS Growth
- 10979.07%
- Country
- France
- Employees
- 3,641
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Bastide le Confort Medical Business Overview & Revenue Model
Company Description
Bastide Le Confort Médical SA specializes in the provision, through both sales and rentals, of medical equipment across France. The company offers a comprehensive array of items, encompassing comfort and wellness products such as specialized seating...
Bastide le Confort Medical Financial Statement Overview
Summary
A balance-sheet repair story with dependable cash generation. Operating profitability is quietly improving (EBIT up to €44.2M, 9.2% margin; EBITDA €104.9M at 21.7%), and the company generated €81.8M of operating cash and €30.8M of free cash flow despite heavy rental-equipment capex. Debt was cut sharply from €411M to €299M while equity nearly doubled to €131M, lowering leverage from 5.7x to 2.3x. Offsetting this, revenue has slipped two years running to €482M, the headline €58.1M net profit appears largely one-off (it exceeds operating profit and is unsupported by cash flow), underlying net profitability is thin, and leverage remains elevated for a capital-intensive care provider.
Income Statement
63PositiveBalance Sheet
62PositiveCash Flow
67Positive| Breakdown | TTM | Jun 2026 | Sep 2025 | Sep 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 482.39M | 482.39M | 491.18M | 529.75M | 508.03M | 468.30M |
| Gross Profit | 50.87M | 50.87M | 333.00M | 354.44M | 333.73M | 306.80M |
| EBITDA | 104.85M | 104.85M | 102.03M | 107.20M | 98.15M | 89.83M |
| Net Income | 58.10M | 58.10M | 528.00K | -900.00K | 12.05M | 13.68M |
Balance Sheet | ||||||
| Total Assets | 575.80M | 575.80M | 661.03M | 647.07M | 657.08M | 632.55M |
| Cash, Cash Equivalents and Short-Term Investments | 48.21M | 48.21M | 25.49M | 23.62M | 36.71M | 22.13M |
| Total Debt | 299.13M | 299.13M | 411.16M | 408.65M | 427.39M | 419.23M |
| Total Liabilities | 444.98M | 444.98M | 589.73M | 566.34M | 568.99M | 545.89M |
| Stockholders Equity | 131.07M | 131.07M | 72.13M | 79.77M | 87.65M | 84.56M |
Cash Flow | ||||||
| Free Cash Flow | 30.77M | 30.77M | 41.74M | 10.64M | 36.65M | -6.51M |
| Operating Cash Flow | 81.78M | 81.78M | 101.82M | 66.04M | 90.28M | 46.76M |
| Investing Cash Flow | 60.08M | 60.08M | -56.44M | -43.65M | -76.27M | -104.74M |
| Financing Cash Flow | -118.31M | -118.31M | -4.33M | -35.55M | -7.89M | 29.43M |
Bastide le Confort Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Neutral. The current price of 19.98 is above the 20-day moving average (MA) of 18.62, above the 50-day MA of 19.73, and below the 200-day MA of 23.07, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 58.32 is Neutral, neither overbought nor oversold. The STOCH value of 82.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BLC.
Bastide le Confort Medical Peers Comparison
Overall Rating
FR:BIM73Outperform
FR:AI66Neutral
FR:BOI65Neutral- FR:BLC61Neutral
FR:ALCGM60Neutral
FR:VTR39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:BIM | 73Outperform | EUR 10.89B | 23.49 | 11.01% | 1.06% | -3.18% | 22.52% |
| FR:AI | 66Neutral | EUR 122.39B | 33.02 | 13.42% | 1.59% | -1.30% | 3.05% |
| FR:BOI | 65Neutral | EUR 337.23M | 12.79 | 6.82% | 7.09% | -1.80% | 35.22% |
| FR:BLC | 61Neutral | EUR 143.19M | 2.52 | 49.70% | ― | -1.79% | 10979.07% |
| FR:ALCGM | 60Neutral | EUR 132.75M | -9.05 | -5.44% | ― | -0.98% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:VTR | 39Underperform | EUR 48.11M | -1.33 | -15.20% | ― | 8.96% | 41.13% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:BLC | Bastide le Confort Medical | 19.98 | -6.52 | -24.60% | |
| FR:AI | Air Liquide (UK) | 192.84 | 40.58 | 26.65% | |
| FR:BIM | bioMerieux SA | 92.30 | -13.84 | -13.04% | |
| FR:BOI | Boiron SA | 19.05 | -5.68 | -22.96% | |
| FR:ALCGM | Cegedim SA | 9.68 | -2.37 | -19.67% | |
| FR:VTR | Vitura SA | 2.80 | -1.80 | -39.13% |
Bastide le Confort Medical Corporate Events
Bastide Reports 7.5% Revenue Growth in First Quarter
Groupe Bastide reported first-quarter 2026-2027 revenue of €124.3 million, up 7.5% on a reported basis and 7.1% organically from restated prior-year figures. Home Healthcare Services grew 8.4% on a reported basis, while Homecare revenue increased 6.2...
Bastide Publishes 2026-2027 Financial Publication Calendar
On November 9, 2026, Bastide published its 2026-2027 publication calendar, with first-quarter revenue scheduled for November 12, 2026, after market close. The timetable also includes first-half revenue and results in February and March 2027, third-qu...
Bastide Publishes Annual Financial and Audit Reports
Bastide le Confort Medical announced the publication of its annual financial and audit reports as regulated information for Euronext compartments A, B and C. The release confirms the company’s compliance with recurring financial-reporting obligations...
Bastide Sets 2026 Meeting With Dividend and Governance Votes
Bastide le Confort Medical is a French public limited company; the release does not detail its products or market focus. It has called a combined general meeting for Dec. 15, 2026, to review fiscal 2026 accounts and vote on resolutions covering gover...
Bastide Reports October Share and Voting Rights Totals
Bastide le Confort Medical reported its share capital and voting-rights position as of October 31, 2026. The company had 7,468,749 shares, including 7,365,078 ordinary shares and 103,671 preferred shares; theoretical voting rights totaled 11,422,904,...
Bastide boosts profits, cash flow and cuts debt as home healthcare growth accelerates
Groupe Bastide reported 2025-2026 revenue of €482.4m, up 7.7% with organic growth of 7.9%, driven by strong momentum in higher-technology home healthcare services and solid expansion in its Home Care activity. Respiratory and diabetes segments posted...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical has disclosed its share capital structure as of 30 September 2026, reporting a total of 7,468,749 shares, comprising 7,365,078 ordinary shares and 103,671 preference shares. The company also reported 11,631,246 theoretical...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical is a French listed company specializing in medical equipment and home healthcare services, operating in the broader health and medical supplies sector. The group focuses on serving patients and care providers through a port...
Bastide lifts revenue and margins as it outperforms targets and cuts debt
Groupe Bastide reported 2025-2026 annual revenue from continuing operations of €482.9 million, up 7.6% year on year on a restated basis, with organic growth of 7.8% and strong contributions from respiratory and diabetes activities. Including the dive...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical has reported its capital structure and voting rights as of 31 July 2026, disclosing a total of 7,468,749 shares, comprising 7,365,078 ordinary shares and 103,671 preference shares. The company also announced 11,631,516 theo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026